McDermott and Bull executive Search
 

Other News

HealthSnap Partners with Capital Cardiology Associates to Expand Virtual Care Management Platform with New Principal Care Management Program

Partnership broadens HealthSnap’s RPM and CCM platform to offer the industry’s most comprehensive virtual care management platform for health systems MIAMI, Oct. 16, 2024 /PRNewswire/ — HealthSnap, a leading virtual care management company that currently partners with over 150 health…

CardioSight, Inc. Appoints New CEO

BUDAPEST, Hungary, Oct. 15, 2024 /PRNewswire/ — CardioSight, Inc., developers of a revolutionary intra-cardiac visualization and interventional platform, announces the appointment of Steve Motes as Chief Executive Officer effective October 15, 2024. Steve brings to CardioSight more than…

LeMaitre Will Announce Third Quarter 2024 Earnings Results October 31, 2024

BURLINGTON, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2024 financial results on Thursday, October 31, 2024, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.

VS Enrolls First Patient in U.S. Pivotal Intravascular Lithotripsy Study POWER PAD II IDE trial will evaluate safety and efficacy of the Pulse IVL™ system in patients with severely calcified peripheral arterial disease

October 15, 2024 07:58 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Amplitude Vascular Systems (AVS), a medical device company focused on safely and effectively treating severely calcified arterial disease, announced today that it has enrolled the first patient(s) in its U.S. pivotal […]

NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)

SANTA ANA, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced acceptance of an oral presentation on the potential of troculeucel in patients with neurodegenerative disease and stroke, at the 16th World Stroke Congress (“WSC 2024”) to be held in Abu Dhabi, UAE from October 23–26, 2024. Although accepted as an oral presentation, NKGen has opted to showcase troculeucel results in poster format.

Inari Medical Announces Partnership with AVF and NBCA on DEFIANCE Trial

IRVINE, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) — In recognition of World Thrombosis Day, Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced collaborative partnerships with the American Venous Forum (“AVF”) and the National Blood Clot Alliance (“NBCA”) on the DEFIANCE trial. This prospective, multinational, randomized controlled trial (“RCT”) will evaluate and compare clinical outcomes in patients with deep vein thrombosis (“DVT”) treated with Inari’s ClotTriever System versus anticoagulation alone.